BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 34276339)

  • 1. Temporal Ordering of Inflammatory Analytes sTNFR2 and sTREM2 in Relation to Alzheimer's Disease Biomarkers and Clinical Outcomes.
    Pillai JA; Khrestian M; Bena J; Leverenz JB; Bekris LM
    Front Aging Neurosci; 2021; 13():676744. PubMed ID: 34276339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer's Disease Continuum.
    Chen YH; Lin RR; Huang HF; Xue YY; Tao QQ
    Front Aging Neurosci; 2022; 14():848180. PubMed ID: 35847667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroimaging biomarkers and CSF sTREM2 levels in Alzheimer's disease: a longitudinal study.
    Nabizadeh F; Seyedmirzaei H; Karami S
    Sci Rep; 2024 Jul; 14(1):15318. PubMed ID: 38961148
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Pillai JA; Bebek G; Khrestian M; Bena J; Bergmann CC; Bush WS; Leverenz JB; Bekris LM
    Front Aging Neurosci; 2021; 13():638922. PubMed ID: 33716716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal Fluid sTREM2 in Alzheimer's Disease Is Associated with Both Amyloid and Tau Pathologies but not with Cognitive Status.
    Li TR; Lyu DY; Liu FQ;
    J Alzheimers Dis; 2022; 90(3):1123-1138. PubMed ID: 36213998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-3 is associated with sTREM2 and mediates the correlation between amyloid-β and tau pathology in Alzheimer's disease.
    Wang ZB; Ma YH; Sun Y; Tan L; Wang HF; Yu JT;
    J Neuroinflammation; 2022 Dec; 19(1):316. PubMed ID: 36578067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glial activation and inflammation along the Alzheimer's disease continuum.
    Nordengen K; Kirsebom BE; Henjum K; Selnes P; Gísladóttir B; Wettergreen M; Torsetnes SB; Grøntvedt GR; Waterloo KK; Aarsland D; Nilsson LNG; Fladby T
    J Neuroinflammation; 2019 Feb; 16(1):46. PubMed ID: 30791945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimer's disease.
    Hok-A-Hin YS; Del Campo M; Boiten WA; Stoops E; Vanhooren M; Lemstra AW; van der Flier WM; Teunissen CE
    J Neuroinflammation; 2023 May; 20(1):107. PubMed ID: 37147668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease.
    Henjum K; Almdahl IS; Årskog V; Minthon L; Hansson O; Fladby T; Nilsson LN
    Alzheimers Res Ther; 2016 Apr; 8(1):17. PubMed ID: 27121148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.
    Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Schlepckow K; Araque Caballero MÁ; Franzmeier N; Capell A; Fellerer K; Nuscher B; Eren E; Levin J; Deming Y; Piccio L; Karch CM; Cruchaga C; Shaw LM; Trojanowski JQ; Weiner M; Ewers M; Haass C;
    Mol Neurodegener; 2019 Jan; 14(1):1. PubMed ID: 30630532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup.
    Woollacott IOC; Nicholas JM; Heslegrave A; Heller C; Foiani MS; Dick KM; Russell LL; Paterson RW; Keshavan A; Fox NC; Warren JD; Schott JM; Zetterberg H; Rohrer JD
    Alzheimers Res Ther; 2018 Aug; 10(1):79. PubMed ID: 30111356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer's disease.
    Zhao A; Jiao Y; Ye G; Kang W; Tan L; Li Y; Deng Y; Liu J;
    J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36519540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease.
    Ewers M; Franzmeier N; Suárez-Calvet M; Morenas-Rodriguez E; Caballero MAA; Kleinberger G; Piccio L; Cruchaga C; Deming Y; Dichgans M; Trojanowski JQ; Shaw LM; Weiner MW; Haass C;
    Sci Transl Med; 2019 Aug; 11(507):. PubMed ID: 31462511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer's disease.
    Pillai JA; Bena J; Bekris L; Kodur N; Kasumov T; Leverenz JB; Kashyap SR;
    Alzheimers Res Ther; 2023 Mar; 15(1):54. PubMed ID: 36927447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic changes of CSF sTREM2 in preclinical Alzheimer's disease: the CABLE study.
    Ma LZ; Tan L; Bi YL; Shen XN; Xu W; Ma YH; Li HQ; Dong Q; Yu JT
    Mol Neurodegener; 2020 Apr; 15(1):25. PubMed ID: 32276587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble TREM2 Concentrations in the Cerebrospinal Fluid Correlate with the Severity of Neurofibrillary Degeneration, Cognitive Impairment, and Inflammasome Activation in Alzheimer's Disease.
    Španić Popovački E; Babić Leko M; Langer Horvat L; Brgić K; Vogrinc Ž; Boban M; Klepac N; Borovečki F; Šimić G
    Neurol Int; 2023 Jul; 15(3):842-856. PubMed ID: 37489359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration.
    Franzmeier N; Suárez-Calvet M; Frontzkowski L; Moore A; Hohman TJ; Morenas-Rodriguez E; Nuscher B; Shaw L; Trojanowski JQ; Dichgans M; Kleinberger G; Haass C; Ewers M;
    Mol Neurodegener; 2020 Oct; 15(1):57. PubMed ID: 33032659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal Fluid sTREM2 Has Paradoxical Association with Brain Structural Damage Rate in Early- and Late-Stage Alzheimer's Disease.
    Leng F; Zhan Z; Sun Y; Liu F; Edison P; Sun Y; Wang Z;
    J Alzheimers Dis; 2022; 88(1):117-126. PubMed ID: 35491791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble TREM2 changes during the clinical course of Alzheimer's disease: A meta-analysis.
    Liu D; Cao B; Zhao Y; Huang H; McIntyre RS; Rosenblat JD; Zhou H
    Neurosci Lett; 2018 Nov; 686():10-16. PubMed ID: 30171911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.